Clínic Barcelona

A genetic test at the time of diagnosis, useful for predicting treatment response in breast cancer

Researchers at Hospital Clínic and IDIBAPS lead a study in which a genomic test performed at the time of diagnosis in breast cancer is useful to identify the real tumor subtype and provide valuable information regarding prognosis and the tumor response to chemotherapy. When transferred to the clinical practice, allows deciding within a multidisciplinary committee the best treatment and follow-up strategy in each case. The article has been published in the journal BMC Medicine and has been coordinated by Dr. Aleix Prat, head of the Onclology (oncology) Department at Hospital Clínic and the Translational genomics and targeted therapeutics in solid tumors IDIBAPS team. Researchers at the Vall d'Hebron Institute of Oncology (VHIO) and the University of North Carolina have also participated.